scispace - formally typeset
C

Colin D. Weekes

Researcher at Harvard University

Publications -  145
Citations -  11139

Colin D. Weekes is an academic researcher from Harvard University. The author has contributed to research in topics: Pancreatic cancer & Cancer. The author has an hindex of 29, co-authored 125 publications receiving 9014 citations. Previous affiliations of Colin D. Weekes include Anschutz Medical Campus & University of Nebraska Medical Center.

Papers
More filters
Journal ArticleDOI

Guidelines for the use and interpretation of assays for monitoring autophagy (3rd edition)

Daniel J. Klionsky, +2522 more
- 21 Jan 2016 - 
TL;DR: In this paper, the authors present a set of guidelines for the selection and interpretation of methods for use by investigators who aim to examine macro-autophagy and related processes, as well as for reviewers who need to provide realistic and reasonable critiques of papers that are focused on these processes.
Journal ArticleDOI

Patient-derived tumour xenografts as models for oncology drug development

John J. Tentler, +8 more
- 01 Jun 2012 - 
TL;DR: This Review will discuss specific PDTX disease examples illustrating an overview of the opportunities and limitations of these models in cancer drug development, and describe concepts regarding predictive biomarker development and future applications.
Journal ArticleDOI

Pancreatic adenocarcinoma, version 2.2017: Clinical practice guidelines in Oncology

Margaret A. Tempero, +35 more
- 01 Aug 2017 - 
TL;DR: The NCCN Guidelines for Pancreatic Adenocarcinoma focus on diagnosis and treatment with systemic therapy, radiation therapy, and surgical resection, as well as on management of locally advanced unresectable and metastatic disease.
Journal ArticleDOI

Pancreatic Adenocarcinoma, Version 2.2014

Margaret A. Tempero, +32 more
- 01 Aug 2014 - 
TL;DR: These NCCN Guidelines Insights summarize major discussion points from the 2014 NCCn Pancreatic Adenocarcinoma Panel meeting, which focused mainly on the management of borderline resectable and locally advanced disease.
Journal ArticleDOI

MUC1 and HIF-1alpha Signaling Crosstalk Induces Anabolic Glucose Metabolism to Impart Gemcitabine Resistance to Pancreatic Cancer.

Surendra K. Shukla, +37 more
- 10 Jul 2017 - 
TL;DR: A widely prevalent mechanism of resistance to gemcitabine in pancreatic cancer is established, whereby increased glycolytic flux leads to glucose addiction in cancer cells and a corresponding increase in pyrimidine biosynthesis to enhance the intrinsic levels of deoxycytidine triphosphate (dCTP).